Abstract
We describe the details of the magnetic resonance spectroscopy and chemical shift imaging techniques for the human brain which have been developed over the last two decades. With these non-invasive tools, it is now readily possible to repeatedly assay up to 20 common brain metabolites. From the perspective of drug discovery, each of these metabolites could fulfill a number of useful functions: disease biomarker, surrogate marker of drug delivery, surrogate marker of drug efficacy and so on. To facilitate the possible utility of clinical magnetic resonance spectroscopy in future drug discovery, the major portion of the review is devoted to a detailed description of the well-validated neurochemical profiles of many common human brain disorders, for which MRS data now exists. Beyond proton, MRS, the commonest tool provided by the manufacturers of clinical MRI equipment, lays the world of heteronuclear NMR more familiar to chemists. Here too, with relatively little effort it has been possible to define neurochemical profiles of human brain disorders using 13C MRS. The future for drug discovery scientists is discussed. Finally, recognizing that a known feature of MR is the lack of sensitivity, we describe new efforts to harness hyperpolarization, with its 50,000 signal amplification, to conventional MRS.
Keywords: Spectroscopy, metabolites, biomarkers, drug discovery, MR spectroscopy, MRS, molecular imaging, Positron Emission Tomography, PET, neurospectroscopy, ISIS, PRESS, STEAM, CSI, nuclear Overhauser effect, NOE, N-Acetylaspartate, NAA, Creatine, Phosphocreatine, Myo-Inositol, Scyllo-Inositol, astrocytes, pseudodementia, Hepatic encephalopathy, transient ischemic attack (TIA), MELAS, mitochondrial encephalopathy with lactic acidosis, Neonatal hypoxia, Closed Head Trauma, Closed head injury, traumatic brain injury, Toxoplasmosis, CNS lymphoma, progressive multifocal leukoencephalopathy, Cryptococcoma, cytochrome P4502D6, CYP2D6, P-glycoprotein efflux transport, receptor imaging indicators
Current Topics in Medicinal Chemistry
Title: Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Volume: 11 Issue: 1
Author(s): Brian Ross, Thao Tran, Pratip Bhattacharya, D. Martin Watterson and Napapon Sailasuta
Affiliation:
Keywords: Spectroscopy, metabolites, biomarkers, drug discovery, MR spectroscopy, MRS, molecular imaging, Positron Emission Tomography, PET, neurospectroscopy, ISIS, PRESS, STEAM, CSI, nuclear Overhauser effect, NOE, N-Acetylaspartate, NAA, Creatine, Phosphocreatine, Myo-Inositol, Scyllo-Inositol, astrocytes, pseudodementia, Hepatic encephalopathy, transient ischemic attack (TIA), MELAS, mitochondrial encephalopathy with lactic acidosis, Neonatal hypoxia, Closed Head Trauma, Closed head injury, traumatic brain injury, Toxoplasmosis, CNS lymphoma, progressive multifocal leukoencephalopathy, Cryptococcoma, cytochrome P4502D6, CYP2D6, P-glycoprotein efflux transport, receptor imaging indicators
Abstract: We describe the details of the magnetic resonance spectroscopy and chemical shift imaging techniques for the human brain which have been developed over the last two decades. With these non-invasive tools, it is now readily possible to repeatedly assay up to 20 common brain metabolites. From the perspective of drug discovery, each of these metabolites could fulfill a number of useful functions: disease biomarker, surrogate marker of drug delivery, surrogate marker of drug efficacy and so on. To facilitate the possible utility of clinical magnetic resonance spectroscopy in future drug discovery, the major portion of the review is devoted to a detailed description of the well-validated neurochemical profiles of many common human brain disorders, for which MRS data now exists. Beyond proton, MRS, the commonest tool provided by the manufacturers of clinical MRI equipment, lays the world of heteronuclear NMR more familiar to chemists. Here too, with relatively little effort it has been possible to define neurochemical profiles of human brain disorders using 13C MRS. The future for drug discovery scientists is discussed. Finally, recognizing that a known feature of MR is the lack of sensitivity, we describe new efforts to harness hyperpolarization, with its 50,000 signal amplification, to conventional MRS.
Export Options
About this article
Cite this article as:
Ross Brian, Tran Thao, Bhattacharya Pratip, Martin Watterson D. and Sailasuta Napapon, Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery, Current Topics in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/156802611793611850
DOI https://dx.doi.org/10.2174/156802611793611850 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue Title: Myocardial Cell Death: Molecular Mechanisms & Drug Targets)
Cardiovascular & Hematological Agents in Medicinal Chemistry Cell Therapy for Myocardial Regeneration
Current Molecular Medicine Nitrogen Biobank for Cardiovascular Research
Current Cardiology Reviews Models and Methods in Cardiac Imaging for Metabolism Studies
Current Pharmaceutical Design Emerging Role for RBM20 and its Splicing Substrates in Cardiac Function and Heart Failure
Current Pharmaceutical Design Acetylation Control of Cancer Cell Metabolism
Current Pharmaceutical Design Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b
Current Drug Targets Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?
Current Cardiology Reviews Truncated Human Cathepsin L, Encoded by a Novel Splice Variant, Exhibits Altered Subcellular Localization and Cytotoxicity
Protein & Peptide Letters Sirtuins Family- Recent Development as a Drug Target for Aging, Metabolism, and Age Related Diseases
Current Drug Targets Subject Index to Volume 4
Current Gene Therapy Beta3-Adrenoreceptors in Cardiovasular Diseases: New Roles for an “Old” Receptor
Current Drug Delivery Incorporation of Selenocysteine into Proteins Using Peptide Ligation
Protein & Peptide Letters The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology The Anti-Oxidant Properties of Isothiocyanates: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Dynamics of T Cells Repertoire During Trypanosoma cruzi Infection and its Post-Treatment Modulation
Current Medicinal Chemistry Alcohol Use and Cataract
Current Drug Abuse Reviews Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design